1 April 2026 in Hypertension
BACKGROUND: The mGlide RCT (randomized controlled trial) evaluated whether a pharmacist-led, mobile health technology facilitated care model improves hypertension control in diverse populations. METHODS: We recruited adult English, Spanish, or Hmong-speaking patients with uncontrolled hypertension from a large health care system and smaller community clinics serving low-income patients. Participants were randomized 1:1 to mGlide or usual care. The 6-month intervention included daily blood pressure (BP) self-monitoring using a smartphone and wireless monitor, automated app-based data sharing, and responsive medication adjustment by a pharmacist-led provider-team. Comparison participants received a digital monitor. Outcomes included mean 6-month systolic BP (SBP), 12-month sustained BP control, 24-hour ambulatory BP and patient activation. RESULTS: A total of 395 participants (mean age, 66.9 years; 46.6% women; mean [SD] SBP, 143.4 [16.5] mm Hg) were randomized to mGlide (n=198) or usual care (n=197). Mean (SD) 6-month SBP (mm Hg) was lower in the mGlide arm (128.1 [13.9] versus 134.0 [16.0]). The adjusted mean difference between groups for the primary outcome of 6-month SBP favored mGlide: −5.8 mm Hg (95% CI, −8.6 to −3.0), sustained at 12 months (−5.7 mm Hg [−8.7 to −2.6]). The mGlide arm also had a 4.8 mm Hg ( P =0.014) lower 24-hour average ambulatory SBP. The 6-month intervention effect varied significantly by activation level, with a difference of −12.6 mm Hg (−20.5 to −4.8) SBP among the lowest versus −2.5 mm Hg (−6.5 to 1.6) among the highest activation level participants. CONCLUSIONS: A mobile health-facilitated care model with pharmacist-led medication adjustment was effective in lowering BP in diverse populations. Patients with low activation benefited more from the intervention; activation levels may inform efficient intervention selection. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03612271.
25 January 2021 in JMIR Research Protocols
Background: Suboptimal treatment of hypertension remains a widespread problem, particularly among minorities and socioeconomically disadvantaged groups. We present a health system–based intervention with diverse patient populations using readily available smartphone technology. This intervention is designed to empower patients and create partnerships between patients and their provider team to promote hypertension control. Objective: The mGlide randomized controlled trial is a National Institutes of Health–funded study, evaluating whether a mobile health (mHealth)-based intervention that is an active partnership between interprofessional health care teams and patients results in better hypertension control rates than a state-of-clinical care comparison. Methods: We are recruiting 450 participants including stroke survivors and primary care patients with elevated cardiovascular disease risk from diverse health systems. These systems include an acute stroke service (n=100), an academic medical center (n=150), and community medical centers including Federally Qualified Health Centers serving low-income and minority (Latino, Hmong, African American, Somali) patients (n=200). The primary aim tests the clinical effectiveness of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained hypertension control rates at 12 months; describe provider experiences of system usability and satisfaction; examine patient experiences, including medication adherence and medication use self-efficacy, self-rated health and quality of life, and adverse event rates; and complete a cost-effectiveness analysis. Results: To date, we have randomized 107 participants (54 intervention, 53 control). Conclusions: This study will provide evidence for whether a readily available mHealth care model is better than state-of-clinical care for bridging the guideline-to-practice gap in hypertension treatment in health systems serving diverse patient populations. Trial Registration: Clinicaltrials.gov NCT03612271; https://clinicaltrials.gov/ct2/show/NCT03612271 International Registered Report Identifier (IRRID): DERR1-10.2196/25424
19 November 2020 in JMIR Preprints
BACKGROUND Suboptimal treatment of hypertension remains a widespread problem, particularly among minorities and socioeconomically disadvantaged groups. We present a health system–based intervention with diverse patient populations using readily available smartphone technology. This intervention is designed to empower patients and create partnerships between patients and their provider team to promote hypertension control. OBJECTIVE The mGlide randomized controlled trial is a National Institutes of Health–funded study, evaluating whether a mobile health (mHealth)-based intervention that is an active partnership between interprofessional health care teams and patients results in better hypertension control rates than a state-of-clinical care comparison. METHODS We are recruiting 450 participants including stroke survivors and primary care patients with elevated cardiovascular disease risk from diverse health systems. These systems include an acute stroke service (n=100), an academic medical center (n=150), and community medical centers including Federally Qualified Health Centers serving low-income and minority (Latino, Hmong, African American, Somali) patients (n=200). The primary aim tests the clinical effectiveness of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained hypertension control rates at 12 months; describe provider experiences of system usability and satisfaction; examine patient experiences, including medication adherence and medication use self-efficacy, self-rated health and quality of life, and adverse event rates; and complete a cost-effectiveness analysis. RESULTS To date, we have randomized 107 participants (54 intervention, 53 control). CONCLUSIONS This study will provide evidence for whether a readily available mHealth care model is better than state-of-clinical care for bridging the guideline-to-practice gap in hypertension treatment in health systems serving diverse patient populations. CLINICALTRIAL Clinicaltrials.gov NCT03612271; https://clinicaltrials.gov/ct2/show/NCT03612271 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25424
17 April 2024 in JMIR Preprints
BACKGROUND The mGlide randomized clinical trial (RCT) is an NIH-funded study, evaluating whether a mobile health (mHealth)-based intervention that facilitates an active partnership between interprofessional health-care teams and patients results better hypertension (HTN) control than a state-of-clinical-care comparison in patients with uncontrolled HTN. The intervention uses readily available smartphone technology. OBJECTIVE The mGlide RCT was implemented in diverse health systems and was ongoing during the pandemic. The protocol was previously published. We describe the differential impact of the pandemic and consequent protocol updates and study timeline changes. METHODS We enrolled participants with uncontrolled HTN who were stroke survivors or primary care patients with elevated cardiovascular disease (CVD) risk from diverse health systems. Planned recruitment sites included primary care clinics and specialty stroke service in an integrated academic health system as well as university-affiliated community clinics and federally qualified health centers (FQHC). The FQHC and community clinics predominantly serve low-income patients and diverse racial/ethnic minorities - including African American, Hmong, and Latino patients. The primary aim tests the clinical effectiveness of reducing SBP of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained HTN control at 12 months, provider experiences of system usability, patient experiences, (including medication adherence, medication use self-efficacy, self-rated health, and quality of life), and adverse event rates. RESULTS Trial recruitment commenced in 2019 and enrollment of 395 participants was completed in August 2023. The last follow-up will be completed in August 2024. The pandemic severely disrupted trial operations. On 3/16/2020, a moratorium on active clinical research was enacted within our health system in order to minimize in-person contact. All mGlide recruitment, enrollment, and follow-up activities ceased. Subsequently, the research team developed remote enrollment and follow-up processes that were utilized until COVID-19 vaccines became available in early 2021. A differential pandemic impact on health system research capacity was noted. The standalone FQHC had the highest rates of study drop-outs and was not able to recover its research capacity post-pandemic. Many clinics, however, including community clinics were impacted in the short-term but recovered their research capacity. Enrollments at the integrated health system were least impacted. Some rural clinics that were added for recruitment later in the study, (September 2022), showed robust participation. The Data Safety Monitoring Board reviewed two interim analyses (December 2021 and October 2022) and recommended that the primary analysis use a continuous endpoint of mean systolic blood pressure difference between the two arms in addition to a dichotomous endpoint of <140 mm Hg. Consequently, the needed sample size was lowered. CONCLUSIONS We describe the dynamics of implementing a technology-based intervention with real-world challenges when participants and healthcare systems are significantly impacted by a disruptive pandemic. CLINICALTRIAL Clinicaltrials.gov: NCT03612271 https://clinicaltrials.gov/study/NCT03612271